Shorter course of treatment may provide better outcome for intermediate-risk prostate cancer

December 5, 2017, Brigham and Women's Hospital
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Prostate cancer is the most common cancer among males in the United States. Approximately, 180,000 men are diagnosed each year, and approximately 95 percent of these men have localized disease that is potentially curable. Previously, studies have consistently demonstrated that conventionally fractionated high dose external beam radiation therapy (CRT), consisting of daily treatment for two months, decreases prostate cancer recurrence, and improves metastasis-free survival. Previous studies also demonstrate that moderate hypo-fractionated radiation therapy (HRT), consisting of daily treatment for one month using a larger dose per treatment, provides a similar low risk of recurrence, and may even be lower with HRT than CRT.

To accurately test the hypothesis of a lower risk of recurrence with HRT, a new study led by investigators at Brigham and Women's Hospital published in European Urology Focus, performed a systematic review and meta-analysis, pooling available data, to assess whether an improved risk of recurrence could be demonstrated using HRT compared with CRT, in addition to assessing the relative impact of these two treatments on bladder and rectal function. Researchers found that the one-month duration HRT, was associated with a significant improvement in recurrence compared to the two-month duration CRT and therefore would be reasonable to consider in men with intermediate risk and who do not have risk factors that could predispose the patient to bladder side effects several years after the treatment is complete.

"Our results provide evidence for clinicians to consider HRT as compared with CRT as a preferred radiation treatment in men with intermediate-risk prostate and at low risk of other complications," stated Trevor Royce, MD, MPH, radiation oncologist at Brigham and Women's Hospital and first author of the study. "Treatment with a shorter course of radiation and higher doses over fewer days may be the preferred approach in appropriately selected patients with localized prostate cancer, reducing treatment time and cost to the patient, and increasing patient convenience and access to treatment."

Researchers analyzed data from over 5,000 men from three randomized studies comparing HRT with CRT in men with prostate cancer. Of the 5,484 men, 3,553 men, or 64.8 percent had intermediate-risk prostate cancer. HRT as compared with CRT was associated with a significant 13 percent reduction in the risk of recurrence. No significant difference in overall survival was found between HRT and CRT but researchers noted that the possibility exists that men in excellent health could also achieve an overall survival benefit with HRT as compared with CRT.

"Late bladder and urethra toxicities were noted to be higher in the HRT as compared to CRT group which necessitates carefully choosing men who are not at risk for sustaining a late bladder or urethral side effect," said Anthony D'Amico, MD, PhD, chief, Genitourinary Radiation Oncology at Brigham and Women's Hospital, and senior author of the study. "Men to exclude would be those who get up more than three times at night to urinate, or have urgency to urinate, or incontinence, or men who are on anti-coagulants that could increase the risk of bleeding," D'Amico said.

Researchers say further study is needed using individual patient-level data among men with high risk cancer to assess the benefit of HRT and whether toxicity, particularly those to the bladder and urinary system are also low with HRT.

Explore further: Markers for prostate cancer death can identify men in need of more aggressive treatment

More information: European Urology (2017). DOI: 10.1016/j.euf.2017.10.011

Related Stories

Markers for prostate cancer death can identify men in need of more aggressive treatment

January 12, 2017
Prostate cancer (PC) is the second leading cause of male cancer death in the United States with an estimated 26,000 deaths in 2016. Two-thirds of all PC deaths observed in the US are men with localized disease who developed ...

Study provides evidence for new approaches to prostate cancer

February 19, 2015
Monitoring prostate cancer (PC) by active surveillance (AS), with the expectation to initiate treatment if the cancer progresses, is a preferred initial option for men with low-risk PC and a life expectancy of at least 10 ...

African-American men negatively impacted by hormone therapy for treatment of prostate cancer

August 4, 2016
In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital found that patients' race significantly affected their longevity by increasing the likelihood of death after receiving ...

Active surveillance preserves quality of life for prostate cancer patients

March 21, 2017
Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released ...

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

February 24, 2015
An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients ...

Increased radiation offers no survival benefit for patients with low-risk prostate cancer

July 16, 2015
Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week ...

Recommended for you

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

Spread of deadly eye cancer halted in cells and animals

November 12, 2018
By comparing genetic sequences in the eye tumors of children whose cancers spread with tumors that didn't spread, Johns Hopkins Medicine researchers report new evidence that a domino effect in cells is responsible for the ...

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Two-pronged device enables maverick immune cells to identify and kill cancers

November 12, 2018
Immune cells called Gamma Delta T cells can act independently to identify and kill cancer cells, defying the conventional view of the immune system, reveals new research from the Francis Crick Institute and King's College ...

Cancer stem cells get energy from protein, and it's proving to be their Achilles' heel

November 12, 2018
Think of energy metabolism like a party popper: Ripping something apart releases a bang. Most of your cells rip apart sugar to release the "bang" of energy. Sometimes they rip apart fats, and in a pinch, cells can even metabolize ...

Research brings personalized medicine to treat leukemia one step closer

November 12, 2018
Scientists at the University of Birmingham have revealed the roles that different types of gene mutations play in causing blood cancers in a study that was the culmination of a decade's research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.